US aid cuts halt HIV vaccine research in South Africa, with global impact
Stop all work, it said. The United States under the Trump administration was withdrawing all its funding.
The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere.
But the $46 million from the U.S. for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home.
South Africa hit hard by aid cuts
South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the country's white Afrikaner minority. The country had been receiving about $400 million a year via USAID and the HIV-focused PEPFAR.
Now that's gone.
Glenda Grey, who heads the Brilliant program, said the African continent has been vital to the development of HIV medication, and the U.S. cuts threaten its capability to do such work in the future.
Significant advances have included clinical trials for lenacapavir, the world's only twice-a-year shot to prevent HIV, recently approved for use by the U.S. Food and Drug Administration. One study to show its efficacy involved young South Africans.
'We do the trials better, faster and cheaper than anywhere else in the world, and so without South Africa as part of these programs, the world, in my opinion, is much poorer,' Gray said.
She noted that during the urgency of the COVID-19 pandemic, South Africa played a crucial role by testing the Johnson & Johnson and Novavax vaccines, and South African scientists' genomic surveillance led to the identification of an important variant.
Labs empty and thousands are laid off
A team of researchers at the University of the Witwatersrand has been part of the unit developing the HIV vaccines for the trials.
Inside the Wits laboratory, technician Nozipho Mlotshwa was among the young people in white gowns working on samples, but she may soon be out of a job.
Her position is grant-funded. She uses her salary to support her family and fund her studies in a country where youth unemployment hovers around 46%.
'It's very sad and devastating, honestly," she said of the U.S. cuts and overall uncertainty. 'We'll also miss out collaborating with other scientists across the continent.'
Professor Abdullah Ely leads the team of researchers. He said the work had promising results indicating that the vaccines were producing an immune response.
But now that momentum, he said, has 'all kind of had to come to a halt.'
The BRILLIANT program is scrambling to find money to save the project. The purchase of key equipment has stopped. South Africa's health department says about 100 researchers for that program and others related to HIV have been laid off. Funding for postdoctoral students involved in experiments for the projects is at risk.
South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not only work on HIV but also tuberculosis — another disease with a high number of cases in the country.
Less money, and less data on what's affected
South Africa's government has said it will be very difficult to find funding to replace the U.S. support.
And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa's HIV program have already been laid off, the government has said. Also gone are the data collectors who tracked patients and their care, as well as HIV counselors who could reach vulnerable patients in rural communities.
For researchers, Universities South Africa, an umbrella body, has applied to the national treasury for over $110 million for projects at some of the largest schools.
During a visit to South Africa in June, UNAIDS executive director Winnie Byanyima was well aware of the stakes, and the lives at risk, as research and health care struggle in South Africa and across Africa at large.
Other countries that were highly dependent on U.S. funding including Zambia, Nigeria, Burundi and Ivory Coast are already increasing their own resources, she said.
'But let's be clear, what they are putting down will not be funding in the same way that the American resources were funding," Byanyima said.
___
Associated Press writer Michelle Gumede in Johannesburg contributed to this report.
___
For more on Africa and development: https://apnews.com/hub/africa-pulse
The Associated Press receives financial support for global health and development coverage in Africa from the Gates Foundation. The AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@


New York Post
3 hours ago
- New York Post
Smithsonian exhibit monkeys around with the scientific evidence on human origins
The Trump Administration recently called out the Smithsonian Institution for pushing 'one-sided, divisive political narratives,' leading GOP Sen. Jim Banks last week to introduce a bill prohibiting the Smithsonian from promoting woke ideology, as The Post exclusively reported. But American history isn't the only domain in which the Smithsonian, with an ideological ax to grind, advances misinformation. The National Museum of Natural History's Hall of Human Origins vastly distorts the scientific evidence on human evolution, seeking to convince visitors that there's nothing special about us as human beings. 'There is only about a 1.2% genetic difference between modern humans and chimpanzees,' the exhibit starts, with large photos of a human and apes. 'You and chimpanzees [are] 98.8% genetically similar.' 6 The Trump Administration recently called out the Smithsonian Institution for pushing 'one-sided, divisive political narratives.' Shutterstock / Paulm1993 No doubt you've heard this statistic before because many science popularizers say the same thing. Yet it's been known for years that these numbers are inaccurate. Thanks to a groundbreaking April paper in the journal Nature, we know just how wrong they are. For the first time, the paper reports 'complete' sequences of the genomes of chimpanzees and other apes done from scratch. When we compare them to humans, we find our genomes are more like 15% genetically different from chimpanzees'. That means the true genetic differences between humans and chimps are more than 10 times greater than what the Smithsonian tells us. The museum distorts human origins in other areas, too. Again, the purpose is to diminish the exceptional place of humans in nature. 6 The David H. Koch Hall of Human Origins exhibit is seen at the Smithsonian's National Museum of Natural History in Washington. AP The museum's Human Origins fossil hall claims the ancient species Sahelanthropus tchadensis was an 'early human' that walked 'on two legs.' But leading paleoanthropologists sharply dispute this claim. A Nature article found that 'Sahelanthropus was an ape,' and many features 'link the specimen with chimpanzees, gorillas or both, to the exclusion of hominids.' A 2020 Journal of Human Evolution paper showed that Sahelanthropus' femur was like that of a chimp-like quadruped — in other words, it didn't walk upright, and it wasn't a human ancestor. 6 The Smithsonian exhibit presents ape-like australopithecines as 'early humans' who walked upright 'on the ground' much like us, but many scientists don't agree with this characterization, according to reports. Courtesy of Casey Luskin Similarly, the Human Origins exhibit presents the ape-like australopithecines as 'early humans' who walked upright 'on the ground' much like us. Some paleoanthropologists agree. But other scientists strongly disagree, pointing out that some australopithecines showed evidence of ape-like knuckle-walking and only limited capacity for running. Their upright-walking ability was likely best suited for walking along tree limbs, not 'on the ground' exactly like we do. Large questions remain about how they walked, and the Smithsonian gives no hint of the scientific controversy. 6 The museum had a display of *Australopithecus africanus* bust in 2010. Courtesy of Casey Luskin The museum's hominid reconstructions also humanize apes while ape-ifying humans. Australopithecus afarensis (the iconic 'Lucy') is portrayed thoughtfully gazing up at the sky, while Australopithecus africanus is presented smiling, perhaps at a friend's wry remark. Yet australopithecines had brains about the size of a chimp's, and there's no fossil evidence they were capable of abstract thought — or humor. We should remember the famed Harvard anthropologist Earnest Hooton's declaration that 'alleged restorations of ancient types of man have very little, if any, scientific value and are likely only to mislead the public.' 6 The exhibit asserts that humans and chimpanzees are '98.8% genetically similar,' but recently published research found our genomes are more like 15% different from chimpanzees. Courtesy of Casey Luskin The Smithsonian's exhibit also gives scientifically misleading support to the idea humans evolved slowly — saying 'we became human gradually,' much as Darwin imagined, from 'earlier primates.' Again, the result is to blur distinctions between us and other creatures. Yet the great Harvard evolutionary biologist Ernst Mayr acknowledged there is a 'large, unbridged gap' in the fossil record between the australopithecines and the first humanlike members of our genus, Homo. In his words, we're in a position of 'not having any fossils that can serve as missing links.' One scientific commentator even said this evidence calls for a 'big bang theory of human evolution.' Why doesn't the Smithsonian disclose any of this information? 6 July marks the 100th anniversary of the Scopes 'monkey' trial. AP This month is the centennial of the Scopes 'monkey' trial, remembered as a warning against hiding scientific information about human evolution. How ironic that 100 years later, the nation's premier science museum obscures scientifically objective data on the very same subject. To fail to correct this exhibit is to use taxpayer money to miseducate the public about a question of profound scientific, sociological, and philosophical importance. Casey Luskin is the Discovery Institute Center for Science and Culture's associate director and co-author of the book 'Science and Human Origins.' He holds a geology Ph.D. from the University of Johannesburg.


New York Post
5 hours ago
- New York Post
3 critical signs of cardiac arrest in the wake of Hulk Hogan's death
Hulk Hogan has wrestled his last match — taken down not by a rival in the ring, but by one of America's top killers: cardiac arrest. News broke Thursday morning that the wrestling icon, born Terry Gene Bollea, had died after weeks of declining health. 'He was suffering from shortness of breath, got tired easily, had lost a lot of weight and was on oxygen as his life ebbed away at his mansion in Clearwater, Florida,' an insider alleged to the Daily Mail. 6 Getty Images While Hogan, 71, may have built his legacy surviving body slams and steel cages, cardiac arrest proved to be one opponent even the handlebar-mustachioed marvel couldn't overpower. Globally, the condition claims more lives each year than colorectal cancer, breast cancer, prostate cancer, pneumonia, car crashes, the flu, HIV and house fires combined, according to the American Heart Association. In the US alone, cardiac arrest kills more than 436,000 Americans every year — making it one of the nation's deadliest health threats. Here's everything you need to know about this heart-stopping emergency and how to act before it's too late. What is cardiac arrest? It's a deadly medical emergency where the heart suddenly stops beating — or beats so erratically that it can't pump blood at all, according to the Cleveland Clinic. 6 Anciens – When that happens, oxygen stops flowing to the brain and vital organs. Within minutes, the body starts shutting down — and without immediate help, the chances of death are high. Despite common confusion, cardiac arrest is not the same as a heart attack. A heart attack is a circulation problem caused by a blocked artery that cuts off blood flow to the heart muscle. Cardiac arrest, by contrast, is an electrical malfunction. The heart's rhythm goes haywire, and the muscle flatlines. Who's at risk for cardiac arrest? The most common cause of sudden cardiac arrest is an irregular heart rhythm called ventricular fibrillation, which keeps the heart from pumping blood effectively, according to the Mayo Clinic. Certain heart conditions — like coronary artery disease, heart valve problems, and a history of heart attacks — can increase the risk of this dangerous rhythm. But cardiac arrest can also strike people with no known heart issues. Other factors that may increase your chances include: Smoking or heavy alcohol/drug use High blood pressure or cholesterol Low potassium or magnesium levels Obesity Diabetes Sleep apnea Chronic kidney disease A sedentary lifestyle A family history of heart disease or cardiac arrest While the risk of cardiac arrest increases with age, it can strike at any time — even in children. In fact, sudden cardiac arrests happen in about 1 in every 70 schools each year, often impacting young athletes. 6 Hulk Hogan had faced a slew of health issues and suffered from a 'weak heart' in the lead-up to his death. George Napolitano / Men generally face higher odds of cardiac arrest, but women's risk rises after menopause. Warning signs to watch for 'The typical signs of a cardiac arrest include abrupt loss of consciousness with eyes rolled back, seizure-like activity due to lack of oxygen flow to the brain, and irregular, labored or no breathing,' Dr. Irfan Asif, professor and chair of the Department of Family and Community Medicine University of Alabama at Birmingham, said in an interview. He added that someone suffering cardiac arrest may have a very weak pulse — or no pulse at all. 6 A sudden collapse is usually the first noticeable sign of sudden cardiac arrest. Rainer Fuhrmann – Other warning signs that can come before cardiac arrest include chest discomfort, shortness of breath, weakness and heart palpitations like a fast-beating, fluttering or pounding heart. But here's the kicker: Sometimes there are no warnings at all. That's why knowing how to respond can mean the difference between life and death. What should you do if someone goes into cardiac arrest? 'If you are experiencing a cardiac arrest, try to get to a place where you are not alone, or signal to someone you are in distress before you are incapacitated,' Dr. John Bozinovski, a cardiac surgeon at The Ohio State University Wexner Medical Center, told HuffPost. If you see someone collapse and suspect cardiac arrest, act fast. First, check if they're responsive by loudly asking, 'Are you okay?' and gently shaking their shoulders. Look for a pulse and check if they're breathing normally, according to the University of California, Davis. 6 AED's are commonly found in public places like airports, schools, shopping malls, office buildings and sporting venues. brostock – If others are nearby, assign someone to call 911 and another to find an automated external defibrillator (AED), which can shock the heart back to rhythm. If you're alone, call 911 yourself and put the phone on speaker. For children, start CPR right away. For adults, get the AED quickly, as it's usually a heart issue. To perform CPR, lay the person on their back on a firm surface, tilt their head back to open the airway, and check for breathing. If they're not breathing, begin chest compressions: place your hands, one on top of the other, in the center of the chest, pressing hard (about 2 inches deep for adults) at 100–120 compressions per minute. 6 CPR can help maintain blood flow and oxygenation until emergency responders arrive. THANAGON – Use the AED as soon as it arrives and follow its prompts. Alternate CPR and AED use until help arrives or the person wakes up. Every minute without intervention after a cardiac arrest lowers survival chances by 10%. Yet fewer than half receive timely help, according to the American Red Cross. While CPR or AED use can double or triple survival odds, studies show bystanders use an AED only 7% of the time and perform CPR 42% of the time when witnessing a public cardiac arrest. Experts are urging everyone to learn CPR to boost those numbers. 'Everyone should take an in-person CPR course at least once, with a refresher every two to three years,' Dr. Eric Goralnick, associate professor of emergency medicine at Harvard Medical School, advised. 'You could save the life of a family member, friend, or even a stranger,' he added, noting that many CPR classes also cover first aid and AED use.